GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa

S D Kotsakis; C C Papagiannitsis; E Tzelepi; N J Legakis; V Miriagou; L S Tzouvelekis

doi:10.1128/AAC.01561-09

GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa

Antimicrob Agents Chemother. 2010 Mar;54(3):1331-3. doi: 10.1128/AAC.01561-09. Epub 2010 Jan 11.

Authors

S D Kotsakis¹, C C Papagiannitsis, E Tzelepi, N J Legakis, V Miriagou, L S Tzouvelekis

Affiliation

¹ Laboratory of Bacteriology, Hellenic Pasteur Institute, Athens, Greece.

Abstract

GES-13 beta-lactamase, a novel GES variant possessing Lys-104 and Asn-170, was identified in Pseudomonas aeruginosa. bla(GES-13) was the single gene cassette of a class 1 integron probably located in the chromosome. GES-13 efficiently hydrolyzed broad-spectrum cephalosporins and aztreonam. Imipenem was a potent inhibitor of GES-13 but was not hydrolyzed at measurable rates.

MeSH terms

Anti-Bacterial Agents / pharmacology
Aztreonam / pharmacology
Cephalosporins / pharmacology
Genetic Variation*
Humans
Integrons / genetics
Microbial Sensitivity Tests
Molecular Sequence Data
Pseudomonas Infections / microbiology
Pseudomonas aeruginosa / drug effects
Pseudomonas aeruginosa / enzymology*
Pseudomonas aeruginosa / genetics
Sequence Analysis, DNA
beta-Lactamases* / biosynthesis
beta-Lactamases* / genetics
beta-Lactams / pharmacology

Substances

Anti-Bacterial Agents
Cephalosporins
beta-Lactams
beta-Lactamases
Aztreonam

Associated data

GENBANK/GU169702